沙库巴曲缬沙坦钠治疗慢性心力衰竭的临床疗效观察

2018-02-18 02:11:14屈晓鹏李敬田
健康大视野 2018年22期
关键词:心功能疗效

屈晓鹏 李敬田

【摘 要】目的:观察沙库巴曲缬沙坦钠治疗慢性心力衰竭的临床疗效。方法:选取2017年12月至2018年2月在我院心内科住院治疗的慢性心力衰竭患者48例(NYHA III、IV级),根据治疗方案分为观察组16例及对照组32例。对照组患者在我科行常规心衰治疗,观察组患者将ACEI/ARB类替换为沙库巴曲缬沙坦钠,两组患者均连续随访4个月。比较两组患者治疗前后临床症状、心功能相关指标,随访期间记录药物不良反应发生情况。结果:(1)两组临床症状均有缓解,但观察者活动耐力大于对照组(P<0.05)。(2)观察组临床评价心功能相关指标优于对照组(P<0.05)。(3)观察组部分患者治疗期间出现低血压。结论:沙库巴曲缬沙坦钠能有效改善慢性心力衰竭患者的症状,并改善心功能,用药期间安全性可控。

【关键词】慢性心力衰竭沙库巴曲缬沙坦钠心功能

Abstract:Objective To observe the clinical efficacy of sirolimus and valsartan sodium in the treatment of chronic heart failure. Methods Forty-eight patients with chronic heart failure who were hospitalized in our department from December 2017 to February 2018 (NYHA III, IV) were enrolled. According to the treatment plan, 16 patients in the observation group and 32 patients in the control group were selected. The patients in the control group underwent conventional heart failure in our department. The patients in the observation group were replaced with the SACI/ARB group as the Shakuba valsartan sodium. The patients in both groups were followed up for 4 months. The clinical symptoms and cardiac function related indexes of the two groups were compared before and after treatment. The adverse drug reactions were recorded during the follow-up period. Results (1) The clinical symptoms of both groups were alleviated, but the activity endurance of the observers was greater than that of the control group (P<0.05). (2) The clinical evaluation of cardiac function in the observation group was superior to the control group (P<0.05). (3) Some patients in the observation group developed hypotension during treatment. Conclusions Shakuba valsartan can effectively improve the symptoms of patients with chronic heart failure, improve heart function, and control the safety during medication.

Key words: chronic heart failure, Shakuba, Qusarsartan, Cardiac function

【中圖分类号】R256.2 【文献标识码】A 【文章编号】1005-0019(2018)22-0-01

心衰是各种心脏疾病的严重表现,目前认为心衰是慢性、自发进展性疾病,神经内分泌系统激活导致心肌重构是引起心衰发生和发展的关键因素。沙库巴曲缬沙坦钠是全球首个血管紧张素受体-脑啡肽酶抑制剂,是一种具有全新作用机制的心力衰竭治疗药物,其在拮抗血管紧张素II受体的同时抑制脑啡肽酶[1-2]。本文主要观察沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效。

1 对象与方法

1.1 研究对象 选取2017年12月至2018年2月在我院心内科住院治疗的慢性心力衰竭患者48例。排除标准:①存在严重的肝肾等脏器障碍者;②安装辅助循环装置者;③合并甲状腺功能亢进性心脏病、心肌炎、重度肺动脉高压、瓣膜性心脏病者;④对本研究存在禁忌症患者。纳入标准均符合慢性心力衰竭的诊断标准。根据治疗方案将所有患者分为观察组16例及对照组32例。……

登录APP查看全文

猜你喜欢
心功能疗效
老年心力衰竭患者BNP及乳酸水平与心功能的相关性
止眩汤改良方治疗痰瘀阻窍型眩晕的临床疗效观察
冷喷联合湿敷甘芩液治疗日晒疮的短期疗效观察
中西医结合治疗慢性盆腔炎的疗效观察
心功能如何分级?
中西医结合治疗舒张性心功能不全临床观察
磷酸肌酸钠用于老年冠心病合并左心功能不全治疗56例分析
脐灸治疗脑卒中后便秘的疗效
冠状动脉支架置入后左心功能变化
四逆汤合葶苈大枣泻肺汤联合西药治疗慢性心功能不全30例
中医研究(2014年2期)2014-03-11 20:28:19